An International Single-Arm Protocol to Provide Expanded Access to Ramucirumab for the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression After Prior Fluoropyrimidine and/or Platinum-Containing Chemotherapy

Trial Profile

An International Single-Arm Protocol to Provide Expanded Access to Ramucirumab for the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression After Prior Fluoropyrimidine and/or Platinum-Containing Chemotherapy

Active, no longer recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 02 Mar 2017

At a glance

  • Drugs Ramucirumab (Primary)
  • Indications Adenocarcinoma; Gastric cancer
  • Focus Expanded access; Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 24 Feb 2017 Status changed from recruiting to active, no longer recruiting.
    • 25 Mar 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 01 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top